Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 3/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | DDO | Q99489 | 1/20 | 0.34 |
| ▸ | NSD2 | O96028 | 1/20 | 0.31 |
| ▸ | CASP6 | P55212 | 1/20 | 0.31 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.30 |
| ▸ | CDK1 | P06493 | 1/20 | 0.30 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.30 |
| ▸ | GSK3B | P49841 | 1/20 | 0.30 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.30 |
| ▸ | CDK5R1 | Q15078 | 1/20 | 0.30 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.30 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12133934 | 0.79 | CYP11B1 (0.60) | CYP11B1CYP11B2MEN1KMT2ACCNB2 | |
| SCHEMBL23352226 | 0.78 | CYP11B1 (0.51) | CYP11B1CYP11B2MEN1KMT2ACCNB2 | |
| SCHEMBL19265379 | 0.76 | CCNB2 (0.31) | CCNB2CDK1CCNB1GSK3BCDK5 | |
| SCHEMBL13912176 | 0.76 | CYP11B1 (0.43) | CYP11B1CYP11B2CCNB2CDK1CCNB1 | |
| SCHEMBL30132809 | 0.76 | CYP11B1 (0.43) | CYP11B1CYP11B2KDM4E | |
| SCHEMBL1356433 | 0.76 | CYP11B1 (0.43) | CYP11B1CYP11B2KDM4E | |
| SCHEMBL11186614 | 0.76 | CYP11B1 (0.40) | CYP11B1CYP11B2 | |
| SCHEMBL2713555 | 0.73 | CYP11B2 (0.41) | CYP11B1CYP11B2 | |
| SCHEMBL18727815 | 0.72 | NSD2 (0.37) | CYP11B1CYP11B2NSD2CASP6CCNB2 | |
| SCHEMBL14228280 | 0.72 | KDM4E (0.38) | CYP11B2KDM4EMEN1ALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8933012-B2 | Glycopeptide antibiotic derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933012-B2 | Glycopeptide antibiotic derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-8933012-B2 | Glycopeptide antibiotic derivative | SHIONOGI & CO., LTD. (JP) | 2015-01-13 | — | — | US | disclosed |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | SHIONOGI & CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
| EP-2030982-A1 | GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2009-03-04 | — | — | EP | disclosed |
| EP-2030982-A1 | GLYCOPEPTIDE ANTIBIOTIC DERIVATIVE | SHIONOGI & CO., LTD. (JP) | 2009-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286717-A1 | Glycopeptide Antibiotic Derivative | NR2C2, NR0B2, NR3C2 | CYP11B1 1254/4885CYP11B2 787/4885KDM4E 4423/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.